TABLE 3.
Analysis by genotype (n = 207) | SNOT improvementa | 95% CI | P |
---|---|---|---|
PAV genotype | 20 | 8 to 32 | 0.001 |
Polyps | 14 | 8 to 20 | <0.001 |
Interaction: genotype/polyps | 0.007 | ||
Male gender | 1 | −4 to 7 | 0.65 |
White | −4 | −12 to 5 | 0.36 |
Age ≥50 years | −3 | −8 to 2 | 0.23 |
Results were likewise significant for the 123 initial patients in the study (p < 0.001 For a difference based on PAV genotype, polyps, and the interaction term). Bole values of p are significant.
Mixed-effects, generalized-least-squares multivariate regression model for change between preoperative SNOT-22 score and postoperative scores at 1, 3, and 6 months. Genotype, age, gender, race/ethnicity, and any significant variables (p < 0.05) on analysis of outcomes were incorporated, as well as an interaction term between genotype and polyp status.
CI = confidence interval; CRS = chronic rhinosinusitis; PAV = functional receptor naplotype containing proline, alanine, and valine; SNOT-22 = 22-item Sino-Nasal Outcome Test.